Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 18, 2021; 11(6): 220-230
Published online Jun 18, 2021. doi: 10.5500/wjt.v11.i6.220
Post-transplant erythrocytosis after kidney transplantation: A review
Beyann Alzoubi, Abish Kharel, Rushad Machhi, Fahad Aziz, Kurtis J Swanson, Sandesh Parajuli
Beyann Alzoubi, Abish Kharel, Rushad Machhi, Fahad Aziz, Kurtis J Swanson, Sandesh Parajuli, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI 53705, United States
Author contributions: Alzoubi B, Kharel A, Machhi R, Swanson KJ and Parajuli S had an original idea, designed the study, reviewed literature, prepared the manuscript; Aziz F edited the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kurtis J Swanson, MD, Academic Fellow, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Madison, 600 Highland Ave, Madison, WI 53705, United States. kswanson@uwhealth.org
Received: February 27, 2021
Peer-review started: February 27, 2021
First decision: May 5, 2021
Revised: May 17, 2021
Accepted: May 24, 2021
Article in press: May 24, 2021
Published online: June 18, 2021
Processing time: 105 Days and 8.9 Hours
Core Tip

Core Tip: Post-transplant erythrocytosis is an important disease process after kidney transplantation that manifests in a typical population based on risk factors, responds well to pharmacotherapy in most cases, and over time, has led to minor sequelae and favorable outcomes with minimal impact on patient and allograft survival. It is important to recognize this disease for appropriate management as well as investigation for other more ominous causes of erythrocytosis, namely malignancy.